Clinical trials: Placebo Effect
Coronary Artery Disease, Angina Pectoris
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI…
- Trial name
- RIVER-PCI (NCT01442038)
- Testing
- Ranolazine
- Where
- 218 sites in United States, Austria and 13 more
- Volunteers
- 2,651 people
- Sponsor
- Gilead Sciences
Hypertension
Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives
The purpose of this study was to evaluate the effect of celecoxib on the efficacy and safety of amlodipine besylate on renal and vascular function in subjects with existing hypertension requiring antihypertensive therapy.
- Trial name
- NCT02979197
- Testing
- OE 10 mg amlodipine besylate tablet, OE 200 mg celecoxib capsule
- Where
- 9 sites in United Kingdom
- Volunteers
- 105 people
- Sponsor
- Kitov Pharma Ltd
Dyslipidaemias, Dyslipidemias
Study to Test GSK256073 in Patients With Dyslipidemia
This is a two part study (Part A and Part B) that will first aim to establish the PK/PD relationship between exposure and lipid effects (Part A: 75 subjects), and will then confirm the effect using the most relevant dose(s) (Part…
- Trial name
- NCT00903617
- Testing
- GSK256073, Niaspan
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Vision, Entoptic
Macular Pigment and Glare Disability
The purpose of this study is: I. To measure MP optical density (MPOD) in two groups (experimental and placebo) of 50 subjects each (N = 100), during an Lutein + Zeaxanthin supplementation period of 12 months. II.
- Trial name
- MP-GD (NCT00909090)
- Testing
- 12 mg Lutein + Zeaxanthin
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- University of Georgia
Cognition
A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability
The purpose is to compare solifenacin and oxybutynin with an inactive tablet and assess any potential effects on mental ability.
- Trial name
- SENIOR (NCT01126424)
- Testing
- Solifenacin, Oxybutynin
- Where
- 3 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
Study With Aminophylline to Attenuate of the Side Effects of Regadenoson
The routine administration of 75 mg of intravenous aminophylline following regadenoson (Lexiscan®), a commonly used medication for nuclear stress testing of the heart, can reduce the gastrointestinal (diarrhea and stomach upset)…
- Trial name
- ASSUAGE (NCT01250496)
- Testing
- Aminophylline
- Where
- United States
- Volunteers
- 248 people
- Sponsor
- Rush University Medical Center
Muscular Dystrophies
First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect
The FTIH study with GSK3439171A will evaluate the safety of GSK3439171A in healthy subjects in order to avoid confounding factors due to the disease or concomitant drugs in patients.
- Trial name
- NCT03627494
- Testing
- GSK3439171A
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis
The primary objective was to estimate the tolerability and safety of 2 doses of Teriflunomide administered once daily for 24 weeks, compared to placebo, in patients with multiple sclerosis [MS] with relapses who were on a stable…
- Trial name
- NCT00475865
- Testing
- Teriflunomide, Glatiramer Acetate (GA)
- Where
- 6 sites in United States, Austria and 4 more
- Volunteers
- 123 people
- Sponsor
- Sanofi
Tranexamic Acid, Burn
TXA Study in Major Burn Surgery
Major surgery can result in blood loss that can require a blood transfusion during and/or after surgery. Tranexamic acid (TXA) is a medication that was first introduced in the 1960's as a treatment for heavy menstrual bleeding.
- Conditions
- Tranexamic Acid, Burn, Major Surgery
- Trial name
- NCT02753816
- Testing
- Tranexamic Acid
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Corewell Health West
Brain Swelling, Brain Edema
Furosemide vs Placebo for Brain Relaxation
Increased brain bulk may be problematic during brain surgery for tumors because it may limit surgical exposure and access to the surgical site.
- Conditions
- Brain Swelling, Brain Edema, Dehydration
- Trial name
- NCT01054404
- Testing
- Furosemide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Northwestern University
Post-Traumatic Stress Disorder
A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)
The purpose of this study is to assess the effects of BNC210 compared to placebo on Post-Traumatic Stress Disorder (PTSD) symptom severity as measured by the Clinician Administered PTSD scale for The Diagnostic and Statistical…
- Trial name
- ATTUNE (NCT04951076)
- Testing
- BNC210
- Where
- 32 sites in United States, United Kingdom
- Volunteers
- 212 people
- Sponsor
- Bionomics Limited
Healthy Volunteers
Study Of Celecoxib In Healthy Subjects
A study to confirm the superiority of celecoxib 100 mg BID to loxoprofen 60 mg TID in the incidence of gastroduodenal endoscopic ulcers after 2 weeks treatment.
- Trial name
- NCT00994461
- Testing
- Celecoxib, Loxoprofen
- Where
- 3 sites in Japan
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy
A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms
The main objective of this trial is to investigate the pharmacodynamic effects of a single dose of BI 1358894 on CCK-4- induced anxiogenic/ panic-like symptoms using the PSS in preselected CCK-4 sensitive healthy volunteers.
- Trial name
- NCT03904576
- Testing
- BI 1358894
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Heart Failure
A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines
In an earlier study, eplerenone was shown to improve survival in patients who had heart failure immediately following a heart attack.
- Trial name
- EMPHASIS-HF (NCT00232180)
- Testing
- Eplerenone
- Where
- 307 sites in United States, Argentina and 27 more
- Volunteers
- 2,743 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Myocardial Infarction
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart…
- Trial name
- NCT04509674
- Testing
- Empagliflozin
- Where
- 439 sites in United States, Argentina and 20 more
- Volunteers
- 6,522 people
- Sponsor
- Boehringer Ingelheim
Lymphoma, Childhood Lymphoma
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
Toxicities related to pediatric cancer treatment can lead to significant illness, organ damage, treatment delays, increased health care cost, and decrease in quality of life.
- Conditions
- Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor
- Trial name
- UVA-Gen001 (NCT02624388)
- Testing
- Genistein
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Virginia
Human Volunteer
A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.
Researchers want to find out how Minocycline Extended-Release Tablets affect sperm-production in healthy males. The study will include Minocycline Extended-Release Tablets, a new once-daily formulation of minocycline, compared…
- Trial name
- NCT00765336
- Testing
- minocycline extended release
- Where
- 10 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medicis Pharmaceutical Corporation
HIV Infections
A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
The primary purpose of this study is to assess the antiviral activity of VH3739937 in Human Immunodeficiency Virus Type-1 (HIV-1) infected treatment naive (TN) participants during monotherapy.
- Trial name
- NCT06061081
- Testing
- VH3739937
- Where
- 18 sites in United States, Argentina and 4 more
- Volunteers
- 21 people
- Sponsor
- ViiV Healthcare
Relapsing-Remitting Multiple Sclerosis (RRMS)
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily oral doses of IMU-838 (vidofludimus calcium), a small molecule inhibitor of…
- Trial name
- EMPhASIS (NCT03846219)
- Testing
- IMU-838 (30 mg/day), IMU-838 (45 mg/day), IMU-838 (10 mg/day)
- Where
- 38 sites in Bulgaria, Poland and 2 more
- Volunteers
- 210 people
- Sponsor
- Immunic AG
Sickle Cell Disease
Voxelotor Neurocognitive Function Study
This is a Phase 3b, randomized, double-blind, placebo-controlled, multicenter study to assess the treatment effect of voxelotor on neurocognitive function as assessed by the National Institute of Health (NIH) Toolbox Cognition…
- Trial name
- NCT05228834
- Testing
- Voxelotor Only Product in Oral Dose Form
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.